Collaboration Combines Trio Health's Curated EMR Data with Navidence's
Computable Operational Definitions to Accelerate Pharma Insights
Aurora, CO, April 2026 - Navidence, a technology company helping healthcare and
life sciences organizations design and assess the use of real-world data (RWD) in
clinical research, today announced a strategic partnership with Trio Health, a leader in EMR data transformation and real-world patient insights. Together, the two companies will deliver more precise, fit-for-purpose real-world evidence (RWE) to
biopharmaceutical companies, CROs, and research organizations across the product lifecycle.
What This Partnership Means for the Life Sciences Market
Biopharmaceutical companies face intensifying pressure to generate robust real-world evidence for regulatory submissions, post-market surveillance, and commercial decision-making. While access to ethically-sourced, high-quality clinical data has grown significantly, the ability to consistently define, query, and analyze that data in a reproducible way remains a major bottleneck.
This collaboration directly addresses that challenge. Trio Health's proprietary
TrioTransform process rapidly captures and curates disease-specific EMR data at
every stage of the patient treatment journey — going beyond raw aggregation to
deliver regulatory-grade, contextualized clinical insights. Navidence's platform enables precise specification of health data requirements through Computable Operational Definitions (CODefs) — standardized, executable queries that translate complex study criteria such as patient cohorts by diagnosis, treatment, or outcome into consistent, computable form across datasets.
By integrating these two capabilities, pharma and life sciences customers will benefit from:
Quotes
"Precisely defining which data is actually needed for a clinical research study has been difficult for life sciences research teams. Pairing Navidence CODefs with Trio Health's advanced AI-agentic data curation approach provides research teams a path to meaningful real-world evidence that is truly designed around the study
purpose."— Aaron Kamauu, CEO, Navidence
"To truly maximize the value of real-world data, we must combine the precision and
rigor of CODefs with sophisticated extraction and curation. It is this unique synergy that allows us to drive a meaningful impact across the entire product lifecycle—from initial discovery to clinical and commercial success." — Brent Clough, CEO, Trio Health
About Navidence Inc.
Navidence is a technology company that helps healthcare and life sciences
organizations design and assess the use of real-world data in clinical research studies and clinical trials. Through its platform and Computable Operational Definitions (CODefs), Navidence enables consistent, transparent, and reproducible analysis of complex real-world data to support smarter research and better patient outcomes. To learn more about Navidence, visit www.navidence.com and follow us on LinkedIn.
About Trio Health
Founded in 2013 and headquartered in Louisville, Colorado, Trio Health transforms
electronic medical record (EMR) data into bespoke, highly curated real-world patient insights not available anywhere else. Through its proprietary TrioTransform process, every data point is not just collected, but curated, contextualized, and optimized for deeper clinical and commercial insights. Trio Health serves biopharmaceutical companies, healthcare providers, and payers with flexible data licensing, full-service analytics, and consulting solutions. To learn more, visit www.triohealth.com.
Media Contacts:
Navidence: Andrew Ecob, andrew.ecob@navidence.com
Trio Health: Kathy Heckman, Kathy.Heckman@triohealth.com